🩺What is Psoriatic Arthritis?
The DAS28 was developed by Prevoo et al. in 1995 and validated as a reliable measure of RA disease activity. The 28-joint count includes shoulders, elbows, wrists, MCPs, PIPs, and knees (excluding hips, ankles, and feet). The composite score incorporates four components: tender joint count (TJC28), swollen joint count (SJC28), acute phase reactant (ESR by Westergren method or CRP), and patient global assessment of disease activity on a 100 mm VAS.
🏥Signs & Symptoms
The following clinical signs and symptoms are commonly assessed when evaluating Psoriatic Arthritis:
- Joint pain, swelling, and morning stiffness
- Swelling of an entire digit (dactylitis)
- Pain at tendon or ligament insertions (enthesitis)
- Low back pain and sacroiliac involvement
- Nail changes: pitting, onycholysis, ridging
- Skin lesions of psoriasis
- Fatigue
🔬Causes & Etiology
Psoriatic arthritis is an inflammatory arthritis that occurs in people with psoriasis, driven by immune-mediated joint and entheseal inflammation.
Genetic predisposition (HLA-B27 and other loci) and environmental triggers interact to cause the disease.
⚠️Risk Factors
The following factors are known to increase the risk of developing or worsening Psoriatic Arthritis:
- Existing psoriasis
- Family history of psoriatic arthritis
- Nail psoriasis
- Severe or widespread skin disease
- HLA-B27 genotype and obesity
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Psoriatic Arthritis:
DAS28 — Disease Activity Score 28 for Rheumatoid Arthritis
The DAS28 (Disease Activity Score 28) is the most widely used composite index for assessing disease activity in rheumatoid arthritis (RA). It combines tender and swollen joint counts (28-joint assessment), acute phase reactant (ESR or CRP), and patient global assessment into a single score for monitoring treatment response and guiding therapy decisions.
BASDAI — Bath Ankylosing Spondylitis Disease Activity Index
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is a validated patient-reported outcome measure that assesses disease activity in ankylosing spondylitis (AS) and axial spondyloarthritis. It consists of six 10-point visual analogue scale (VAS) questions covering fatigue, spinal pain, peripheral joint pain, enthesitis, and morning stiffness.
ACR/EULAR 2010 RA Classification Criteria
The 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) were developed to enable earlier diagnosis and classification of RA compared to the 1987 ACR criteria. The criteria assign points across four domains: joint involvement, serology, acute phase reactants, and symptom duration.
HAQ-DI — Health Assessment Questionnaire Disability Index
The Health Assessment Questionnaire Disability Index (HAQ-DI) is a validated patient-reported outcome measure that assesses functional disability across eight domains of daily living: dressing, arising, eating, walking, hygiene, reach, grip, and activities. It is widely used in rheumatoid arthritis and other rheumatic diseases.
PASI — Psoriasis Area and Severity Index
The Psoriasis Area and Severity Index (PASI) is the most widely used tool for assessing psoriasis severity in clinical trials and practice. It combines the assessment of body surface area involvement with the severity of three clinical features — erythema, induration, and desquamation — across four body regions.
🧬Diagnostic Logic & Scoring Breakdown
The DAS28 is calculated using four components. Tender Joint Count (TJC28): count of painful joints on palpation from the 28-joint assessment (0-28). Swollen Joint Count (SJC28): count of swollen joints from the same 28-joint assessment (0-28). Acute Phase Reactant: either ESR (erythrocyte sedimentation rate in mm/h) using the DAS28-ESR formula, or CRP (C-reactive protein in mg/L) using the DAS28-CRP formula. Patient Global Assessment (PGA): patient-reported overall disease activity on a 0-100 mm visual analogue scale. For DAS28-ESR: 0.56√(TJC) + 0.28√(SJC) + 0.70 ln(ESR) + 0.014(PGA). For DAS28-CRP: 0.56√(TJC) + 0.28√(SJC) + 0.36 ln(CRP+1) + 0.014(PGA) + 0.96. The DAS28-CRP formula includes a correction factor (+0.96) to improve concordance with DAS28-ESR. Interpretation: <2.6 remission, 2.6-3.2 low disease activity, >3.2-5.1 moderate disease activity, >5.1 high disease activity.
📢Clinical Significance & Implications
The DAS28 is the most validated and widely used disease activity measure in rheumatoid arthritis clinical practice and trials. It is endorsed by the American College of Rheumatology (ACR), European Alliance of Associations for Rheumatology (EULAR), and treat-to-target recommendations. The DAS28 has been validated against radiographic progression, functional status (HAQ-DI), and patient-reported outcomes. A change of >0.6 is considered clinically meaningful, and >1.2 represents a major response. The treat-to-target strategy recommends targeting DAS28 <2.6 (remission) or at least <3.2 (low disease activity).
🛡️Prevention & Management
Evidence-based prevention and management strategies for Psoriatic Arthritis include:
- Early diagnosis and treatment to prevent joint damage
- Regular physical activity and joint-friendly exercise
- Weight management, which reduces disease activity
- Smoking cessation
- Adherence to DMARD and biologic therapy where indicated
⚡Complications & Prognosis
Without proper management, Psoriatic Arthritis may lead to the following complications:
Progressive erosive joint damage and deformity without treatment.
Reduced mobility and functional disability over time.
Increased cardiovascular risk associated with chronic inflammatory disease.
💡 Clinical Assessment Scenario Example
A 45-year-old woman with RA: TJC28 = 8, SJC28 = 6, ESR = 35 mm/h, PGA = 60/100. DAS28-ESR = 0.56×√(8) + 0.28×√(6) + 0.70×ln(35) + 0.014×60 = 0.56×2.83 + 0.28×2.45 + 0.70×3.56 + 0.84 = 1.58 + 0.69 + 2.49 + 0.84 = 5.60. High disease activity. Recommendation: Escalate DMARD, consider biologic therapy, urgent rheumatology referral.
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Psoriatic Arthritis:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Including hips, ankles, and feet in the 28-joint count
✅ Correction: The DAS28 specifically uses a 28-joint count excluding hips, ankles, and feet. If these joints are involved, they should be documented separately but do not contribute to the DAS28 score.
❌ Mistake: Using ESR in mm/h and CRP in mg/dL interchangeably without unit conversion
✅ Correction: DAS28-ESR uses ESR in mm/h (Westergren). DAS28-CRP uses CRP in mg/L. If CRP is reported in mg/dL, multiply by 10 to convert to mg/L before using the formula.
❌ Mistake: Using BASDAI alone without ASDAS for treatment decisions
✅ Correction: While BASDAI ≥4 is commonly used for biologic eligibility, the ASDAS (Ankylosing Spondylitis Disease Activity Score) incorporating CRP provides more objective assessment and better discrimination. Use both BASDAI and ASDAS when available.
❌ Mistake: Not accounting for patient circadian variation in morning stiffness reporting
✅ Correction: Morning stiffness is best assessed when the patient is actively experiencing it. Ideally, the questionnaire should be completed in the morning before significant activity. Patients who complete it in the afternoon or evening may underestimate stiffness duration and severity.
❌ Mistake: Applying the criteria to patients without objective synovitis (e.g., arthralgia only)
✅ Correction: The criteria require at least one clinically swollen joint on examination. Do not apply to patients with joint pain without swelling or to those with non-inflammatory joint diseases.
❌ Mistake: Counting all joints including DIPs, first MTP, and first CMC in the joint score
✅ Correction: DIPs of hands and feet, first MTP joints, and first CMC joints are excluded from the joint count per the criteria definition.
❌ Mistake: Scoring serology based on RF alone without anti-CCP or vice versa
✅ Correction: Both RF and anti-CCP should be tested. Score the highest applicable category from the combined serology: if both are low-positive, score remains 2; if either is high-positive, score becomes 3.
❌ Mistake: Using the criteria to exclude RA diagnosis in seronegative patients with typical RA presentation
✅ Correction: Patients can meet the criteria through joint involvement alone (0-5 points) plus acute phase (1 point) and duration (1 point) for a total of 7/10, even with negative serology. The criteria are for classification, not diagnosis — clinical judgment remains paramount.
❌ Mistake: Not adjusting domain scores upward when the patient uses aids or devices
✅ Correction: According to the standard HAQ scoring, if a patient uses aids, devices, or requires assistance from another person for a domain, the minimum score for that domain should be 2 (with much difficulty), even if the patient reports less difficulty. This adjustment ensures accurate representation of true functional status.
❌ Mistake: Using HAQ-DI alone without assessing disease activity (DAS28)
✅ Correction: HAQ-DI measures functional disability, which is influenced by both disease activity and structural damage. It should be interpreted alongside disease activity measures like DAS28 to differentiate active inflammation from permanent joint damage as a cause of disability.
❌ Mistake: Using BSA alone instead of full PASI calculation.
✅ Correction: BSA measures only extent without severity. PASI combines both for a comprehensive assessment.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Psoriatic Arthritis; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: What is the difference between DAS28-ESR and DAS28-CRP?
DAS28-ESR uses the erythrocyte sedimentation rate (Westergren method) while DAS28-CRP uses C-reactive protein. DAS28-CRP includes a correction factor of +0.96 to better align with DAS28-ESR. CRP is less affected by age, sex, and immunoglobulins than ESR, making it more specific for inflammation. However, clinical trials traditionally used DAS28-ESR. Both are acceptable for clinical practice, but the same formula should be used consistently for longitudinal monitoring of individual patients.
Q: How often should DAS28 be measured?
The treat-to-target strategy recommends assessing disease activity with DAS28 every 1-3 months during active disease to guide treatment adjustments. Once the treatment target (remission or low disease activity) is achieved and sustained, monitoring can be extended to every 3-6 months. More frequent assessment may be needed when tapering therapy or during flares.
Q: What BASDAI score qualifies for biologic therapy in AS?
Most guidelines (ASAS, NICE, ACR) use BASDAI ≥4 (on a 0-10 scale) as a threshold for active disease warranting biologic therapy initiation, along with failed response to at least two NSAIDs for 4 weeks each. Additionally, the patient should have an abnormal CRP or MRI evidence of active sacroiliitis. Some guidelines also require a second measure (ASDAS ≥2.1 or physician global assessment) for confirmation.
Q: What is the minimum clinically important difference for BASDAI?
The minimum clinically important difference (MCID) for BASDAI is 1 point (on a 0-10 scale). A 50% improvement or a decrease of 2 points is considered a major clinical response. The BASDAI 50 (50% improvement) is a common endpoint in AS clinical trials.
Q: How do the 2010 ACR/EULAR criteria differ from the 1987 ACR criteria?
The 2010 criteria differ in several key ways: (1) They do not require radiographic erosions or rheumatoid nodules, enabling earlier diagnosis; (2) They use a weighted scoring system rather than a checklist; (3) They include anti-CCP antibodies separately from RF; (4) They incorporate acute phase reactants; (5) They emphasize small joint involvement; (6) They establish a minimum symptom duration of 6 weeks rather than the 1987 requirement for 6 weeks of arthritis. These changes improved sensitivity for early RA from approximately 0.50 (1987) to 0.84 (2010), with maintained specificity of 0.91.
Q: Can patients with seronegative RA be classified using these criteria?
Yes. Joint involvement (up to 5 points) combined with acute phase reactants (1 point) and symptom duration (1 point) can yield a score of 7/10 even with negative serology, meeting the threshold for definite RA. However, careful exclusion of alternative diagnoses is especially important in seronegative patients, as conditions like psoriatic arthritis, reactive arthritis, and SLE may also present with polyarthritis.
Q: Should the criteria be applied in primary care or only in rheumatology settings?
The criteria were developed and validated in rheumatology clinic populations. While they can be used in primary care as a screening tool, they perform with lower specificity in this setting due to the higher prevalence of non-inflammatory joint conditions. Any patient meeting the criteria in primary care should be referred to rheumatology for confirmation and management. The joint count requires clinical expertise to distinguish synovitis from periarticular swelling.
Q: What is the minimal clinically important difference (MCID) for HAQ-DI?
The MCID for HAQ-DI is approximately 0.22-0.25 points on the 0-3 scale. In clinical trials, a change of 0.22-0.25 is considered a small but meaningful improvement. A change of 0.5 is considered moderate improvement, and a change of 1.0 or more is considered major improvement. The HAQ-DI is sensitive to change with effective DMARD therapy.
Q: Can HAQ-DI distinguish between disability from active inflammation vs permanent joint damage?
The HAQ-DI measures overall functional status but does not distinguish between reversible disability from active inflammation and irreversible disability from structural joint damage. To make this distinction, HAQ-DI should be interpreted alongside disease activity measures (DAS28, CRP/ESR) and imaging findings. Improvement in HAQ-DI with treatment suggests reversible inflammatory component, while persistent HAQ-DI elevation despite controlled inflammation suggests structural damage.
Q: What PASI score indicates severe psoriasis?
PASI < 10 = mild, 10-20 = moderate, > 20 = severe. A PASI > 10 is generally considered moderate-to-severe.
📚Evidence-Based References
Medically Reviewed By
Dr. Mahmoud El-Sayed
MD, Rheumatology | Rheumatology
Dr. Mahmoud El-Sayed is a consultant rheumatologist with expertise in inflammatory arthritis, autoimmune diseases, and clinical immunology.
View editorial & review policy →